MazF gene therapy (Takara Bio)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameMazF gene therapy (Takara Bio)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector
Mechanisms of ActionT-cell surface antigen CD4 modulatorsRibonucleases stimulants
TargetsRibonucleasesT-cell surface antigen CD4
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTakara Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesTakara Bio Inc
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A